Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease.

OBJECTIVE To identify single-nucleotide polymorphisms (SNPs) associated with risk and age at onset of Alzheimer disease (AD) in a genomewide association study of 469 438 SNPs. DESIGN Case-control study with replication. SETTING Memory referral clinics in Canada and the United Kingdom. PARTICIPANTS The hypothesis-generating data set consisted of 753 individuals with AD by National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association criteria recruited from 9 memory referral clinics in Canada and 736 ethnically matched control subjects; control subjects were recruited from nonbiological relatives, friends, or spouses of the patients and did not exhibit cognitive impairment by history or cognitive testing. The follow-up data set consisted of 418 AD cases and 249 nondemented control cases from the United Kingdom Medical Research Council Genetic Resource for Late-Onset AD recruited from clinics at Cardiff University, Cardiff, Wales, and King's College London, London, England. MAIN OUTCOME MEASURES Odds ratios and 95% confidence intervals for association of SNPs with AD by logistic regression adjusted for age, sex, education, study site, and French Canadian ancestry (for the Canadian data set). Hazard ratios and 95% confidence intervals from Cox proportional hazards regression for age at onset with similar covariate adjustments. RESULTS Unadjusted, SNP RS4420638 within APOC1 was strongly associated with AD due entirely to linkage disequilibrium with APOE. In the multivariable adjusted analyses, 3 SNPs within the top 120 by P value in the logistic analysis and 1 in the Cox analysis of the Canadian data set provided additional evidence for association at P< .05 within the United Kingdom Medical Research Council data set: RS7019241 (GOLPH2), RS10868366 (GOLPH2), RS9886784 (chromosome 9), and RS10519262 (intergenic between ATP8B4 and SLC27A2). CONCLUSIONS Our genomewide association analysis again identified the APOE linkage disequilibrium region as the strongest genetic risk factor for AD. This could be a consequence of the coevolution of more than 1 susceptibility allele, such as APOC1, in this region. We also provide new evidence for additional candidate genetic risk factors for AD that can be tested in further studies.

[1]  B. Reisberg,et al.  The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.

[2]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[3]  Gerda G. Fillenbaum,et al.  Multidimensional Functional Assessment of Older Adults: The Duke Older Americans Resources and Services Procedures , 1988 .

[4]  Isabelle Rouleau,et al.  Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease , 1992, Brain and Cognition.

[5]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.

[6]  M A Pericak-Vance,et al.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. , 1993, Neurology.

[7]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[8]  M. Folstein,et al.  Population-based norms for the Mini-Mental State Examination by age and educational level. , 1993, JAMA.

[9]  Canadian study of health and aging: study methods and prevalence of dementia. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[10]  F. Fazekas,et al.  The Mattis Dementia Rating Scale , 1994, Neurology.

[11]  K. Roeder,et al.  Genomic Control for Association Studies , 1999, Biometrics.

[12]  R. Kladney,et al.  GP73, a novel Golgi-localized protein upregulated by viral infection , 2000, Gene.

[13]  T. Nagase,et al.  Prediction of the coding sequences of unidentified human genes. XXII. The complete sequences of 50 new cDNA clones which code for large proteins. , 2001, DNA research : an international journal for rapid publication of reports on genes and genomes.

[14]  M. Albert,et al.  Results of a high-resolution genome screen of 437 Alzheimer's disease families. , 2003, Human molecular genetics.

[15]  Yasunori Hayashi,et al.  The Importance of Dendritic Mitochondria in the Morphogenesis and Plasticity of Spines and Synapses , 2004, Cell.

[16]  Lefkos Middleton,et al.  Disease-specific target selection: a critical first step down the right road. , 2005, Drug discovery today.

[17]  Chad Haynes,et al.  PAWE-3D: visualizing power for association with error in case-control genetic studies of complex traits , 2005, Bioinform..

[18]  R. Mahley,et al.  Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Owen,et al.  Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[20]  D. Galati,et al.  Accumulation of Amyloid Precursor Protein in the Mitochondrial Import Channels of Human Alzheimer’s Disease Brain Is Associated with Mitochondrial Dysfunction , 2006, The Journal of Neuroscience.

[21]  A D Roses,et al.  Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.

[22]  Michael R. Barnes,et al.  Navigating the HapMap , 2006, Briefings Bioinform..

[23]  G. Abecasis,et al.  Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies , 2006, Nature Genetics.

[24]  Terence P. Speed,et al.  Genome analysis A genotype calling algorithm for affymetrix SNP arrays , 2005 .

[25]  Winnie S. Liang,et al.  GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. , 2007, Neuron.

[26]  Yaakov Stern,et al.  The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. , 2007, Archives of neurology.

[27]  A D Roses,et al.  Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease) , 2007, The Pharmacogenomics Journal.

[28]  Peter Kraft,et al.  Drinking from the fire hose--statistical issues in genomewide association studies. , 2007, The New England journal of medicine.

[29]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[30]  Allan R. Jones,et al.  Genome-wide atlas of gene expression in the adult mouse brain , 2007, Nature.

[31]  J. Hirschhorn,et al.  Genetic model testing and statistical power in population‐based association studies of quantitative traits , 2007, Genetic epidemiology.

[32]  Winnie S. Liang,et al.  GAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 Carriers , 2007, Neuron.

[33]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[34]  P. Donnelly,et al.  Replicating genotype–phenotype associations , 2007, Nature.

[35]  K. Lunetta,et al.  The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease , 2007, Nature Genetics.

[36]  M. Gill,et al.  Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. , 2007, Human molecular genetics.

[37]  Rebecca F. Halperin,et al.  A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. , 2007, The Journal of clinical psychiatry.